Related Experiment Video
Updated: Jun 24, 2026
09:57
Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy
Published on: September 20, 2024
Favourable prognostic factors with infantile spasms
1Kuopio University Hospital, Kuopio, P.O. Box 1627, FI-70211 Kuopio, Finland. raili.riikonen@kuh.fi
Summary
Favorable outcomes in infantile spasms depend on early treatment and response, regardless of cause. Prognosis can be predicted early, with factors like age at onset and seizure type influencing outcomes.
Area of Science:
- Pediatric Neurology
- Developmental Neuroscience
- Clinical Pediatrics
Background:
- Infantile spasms (IS) are a severe epilepsy syndrome in infants.
- Understanding factors influencing IS prognosis is crucial for management.
Purpose of the Study:
- To review the influence of etiology and treatment on infantile spasms outcomes.
- To identify predictors of outcome and potential strategies for improving prognosis.
Main Methods:
- Review of existing literature on infantile spasms etiology, treatment, and outcome.
- Analysis of factors associated with favorable and unfavorable prognoses.
Main Results:
- Favorable factors include cryptogenic etiology, later onset, absence of atypical seizures, and early treatment response.
- Hormonal therapy may show better short-term outcomes than vigabatrin, though seizure freedom rates are similar.
- Early treatment response predicts cognitive outcome in cryptogenic IS.
Conclusions:
- Prognosis for infantile spasms can be predicted early in the disease course.
- Early intervention and tailored treatment are key to improving outcomes.
- Further research into visual field assessment for vigabatrin risks is needed.
More Related Videos
Related Concept Videos
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:31Skeletal Muscle Relaxants: Therapeutic Uses
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
01:13Seizures: Classification
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
01:29Spasmolytic Agents: Chemical Classification
Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also promote...
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also promote...